Sugi Predict

Sugi Predict / Compounds / SCHEMBL419615

SCHEMBL419615

SCHEMBL419615

O=C(O)C(O)(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ HIF1A Q16665 1/20 0.59
▸ CYP1A2 P05177 4/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ FDPS P14324 1/20 0.52
▸ CES1 P23141 2/20 0.46
▸ CES2 O00748 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ SLC13A5 Q86YT5 2/20 0.44
▸ MMP8 P22894 1/20 0.44
▸ KEAP1 Q14145 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ TAAR1 Q96RJ0 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ARG1 P05089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3730337 0.89 SMN1; SMN2 (0.53) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL7908936 0.87 SMN1; SMN2 (0.52) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL7300860 0.87 SLC13A5 (0.56) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL7908766 0.87 SMN1; SMN2 (0.52) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL27639696 0.87 SMN1; SMN2 (0.62) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL10029155 0.87 SMN1; SMN2 (0.52) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL687447 0.87 SMN1; SMN2 (0.52) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL10941763 0.86 SLC13A5 (0.54) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL9554595 0.84 SMN1; SMN2 (0.53) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19
SCHEMBL9554586 0.84 SMN1; SMN2 (0.53) SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140343039-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2014-11-20 — — US claimed
US-20120022250-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2012-01-26 — — US claimed
WO-2010103405-A2 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS ROBIN JEAN-PIERRE (CH) 2010-09-16 — — WO claimed
CN-119161358-B 4,5,6, 7-Tetrahydrothiophene [2,3-c ] pyridine-3-carboxamide compound and preparation method and application thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2026-05-26 — — CN disclosed
CN-119930715-A 1-Aryl-3- (heterocycle substituted phenyl) urea compound and preparation method and application thereof 沈阳药科大学 2025-05-06 — — CN disclosed
CN-119912506-A 1, 2-Diaza-5-carboxamide compound, preparation method and application thereof 沈阳药科大学 2025-05-02 — — CN disclosed
CN-117800916-B Preparation and application of 1- [ (1H-indazol-7-yl) methyl ] -3-arylthiourea derivative 沈阳药科大学 2025-02-11 — — CN disclosed
CN-118063386-B (E) Preparation and application of (E) -N- [ (1H-indazol-7-yl) methyl ] -3-aryl acrylamide derivative 沈阳药科大学 2025-02-11 — — CN disclosed
CN-119161358-A 4,5,6, 7-Tetrahydrothiophene [2,3-c ] pyridine-3-carboxamide compound and preparation method and application thereof 沈阳药科大学 2024-12-20 — — CN disclosed
CN-118063386-A (E) Preparation and application of (E) -N- [ (1H-indazol-7-yl) methyl ] -3-aryl acrylamide derivative 沈阳药科大学 2024-05-24 — — CN disclosed
CN-117903056-A 2-Substituted acetamido benzamide derivative and application thereof in preparation of anti-influenza virus drugs 沈阳药科大学 2024-04-19 — — CN disclosed
US-6825184-B2 FOR USE AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-11-30 — — US disclosed
US-20030162968-A1 1,4-Disubstituted benzo-fused urea compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-28 — — US disclosed
US-5442044-A Hypotensive agents PFIZER INC. (US) 1995-08-15 — — US disclosed
EP-0661292-A1 Orally active renin inhibitors PFIZER INC. (US) 1995-07-05 — — EP disclosed
EP-0438233-A2 Orally active renin inhibitors PFIZER INC. (US) 1991-07-24 — — EP disclosed
US-4104380-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-08-01 — — US disclosed
US-4104380-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-08-01 — — US disclosed
US-4076937-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-02-28 — — US disclosed
US-4076937-A Dibenzyl glycolic acid derivatives WARNER-LAMBERT COMPANY (US) 1978-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162968-A1 1,4-Disubstituted benzo-fused urea compounds NFKBIA, MPO, RELA SMN1; SMN2 3568/4885HIF1A 532/4885CYP1A2 314/4885
US-20120022250-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS CHRM1, OPRM1, CHRM2 SMN1; SMN2 1910/4885HIF1A 1107/4885CYP1A2 526/4885
US-20140343039-A1 PROCESS FOR PREPARING CEPHALOTAXINE ESTERS CFH, C5, CHRM1 SMN1; SMN2 2218/4885HIF1A 1226/4885CYP1A2 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.